Product class: Authorized package
Medicinal product class: For human use
Package code: 3064092
Name of medicinal product: AZACITIDINE KABI
Active substances:
Estonian, English, Latin
ATC code: L01BC07
Dosage form: powder for suspension for injection
Route of administration: subcutaneous use
Strengh: 100mg
Amount in package: 1TK
Legal status for supply*: Subject to medicinal prescription
Class of active substance:  
Additional information:  
Indication: Azacitidine Kabi is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: • Intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the international prognostic scoring system (IPSS), • Chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts withoutmyeloproliferative disorder, • Acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according toWorld Health Organisation (WHO) classification, • AML with > 30% marrow blasts according to the WHO classification.
Safety features: Yes
Summary of product characteristics (SPC):
Package information leaflet (PIL): EST
Last imported to Estonia: Never imported to Estonia
Marketing authorization holder: Fresenius Kabi Deutschland GmbH 
Marketing authorization number: EU/1/23/1777 
Marketing authorization issued on: 09 January 2024 
Marketing authorization expires on: 09 January 2029 
Marketing authorization procedure type: Centralised 
Reference price:   
Under reference price:   
Reference price of daily dose:   
Entry/Changing date: 05 March 2024
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription